Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group.
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Start Page
Article number 103696
ISSN
1556-1380
Date Issued
2026-03-26
Author(s)
Tan, Aaron C
Li, Molly
Lee, David
Uehara, Yuji
Thamlikitkul, Lucksamon
Zhang, Jia-Tao
Zheng, Meimei
Lee, Chee Khoon
Pavlakis, Nick
John, Thomas
Soo, Ross A
Skanderup, Anders
Voon, Pei Jye
Ahn, Beung-Chul
Park, Sehhoon
Hayashi, Hidetoshi
Goto, Yasushi
Horinouchi, Hidehito
Yatabe, Yasushi
Reungwetwattana, Thanyanan
Kim, Dong-Wan
Mok, Tony
Tan, Daniel S W
Wu, Yi-Long
Ahn, Myung-Ju
Abstract
Minimal residual disease (MRD) detection using liquid biopsy is an emerging tool for risk stratification and monitoring for recurrence in resected early stage NSCLC. There is increasing need for clear guidance on its optimal clinical implementation.
The Asian Thoracic Oncology Research Group (ATORG) convened a multidisciplinary panel of 27 experts to develop a consensus statement on the clinical application of circulating tumor DNA-based MRD testing in early stage resected NSCLC, using a structured Delphi methodology. Statements were organized into the following broad thematic domains: assay validity and standardization; harmonization in research and trials; clinical application; challenges in implementation; consensus recommendations; infrastructure for regional MRD adoption; and roadmap for pragmatic trials.
A total of 23 position statements were developed, of which all except one achieved strong consensus. The consensus highlighted the need to define minimum analytical performance thresholds for MRD assays, improve standardization of reporting metrics, and clear guidelines for pre-analytical handling. Harmonization of blood sampling time points and terminology across clinical trials is also essential to confirm the prognostic value of MRD assays. Although current MRD assays demonstrate high specificity and positive predictive value, variable sensitivity precludes routine use for adjuvant therapy de-escalation outside clinical trials. Broader access, sustainable funding, ongoing consensus building, and collaborative real-world data generation are also critical to support clinical implementation and adoption. Future clinical trials must account for the distinct biology and changing standards of care associated with different driver genes.
These consensus recommendations provide a pragmatic framework to guide the responsible integration of MRD testing into clinical research and practice.
Subjects
Circulating tumor DNA
Early stage
Minimal residual disease
Non–small cell lung cancer
Type
journal article